ID2 and hepatocellular carcinoma: To assess the role of Id2 in hepatoma development and progression, we administered DEN to Id2fl/flCd4-Cre− mice and Id2fl/flCd4-Cre+ mice on postnatal day 14 and monitored tumor development in the following 40 weeks (Fig. 3A).